Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28668744 | 0.99 | TAAR1 (0.65) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL21550896 | 0.95 | TAAR1 (0.60) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL15952657 | 0.86 | KIT (0.54) | TAAR1KITALDH1A1SLC6A7ALKBH1 | |
| SCHEMBL2309052 | 0.86 | NTRK1 (0.64) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL15953346 | 0.85 | KIT (0.53) | TAAR1KITALDH1A1HSD17B10SLC6A7 | |
| SCHEMBL26077214 | 0.85 | KIT (0.53) | TAAR1KITALDH1A1HSD17B10SLC6A7 | |
| SCHEMBL21551599 | 0.85 | TAAR1 (0.49) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL22411589 | 0.85 | NTRK1 (0.63) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL28927093 | 0.82 | CYP11B2 (0.62) | KITPRMT5ALDH1A1HPGDHSD17B10 | |
| SCHEMBL18740315 | 0.81 | NTRK1 (0.60) | TAAR1SLC6A2SLC6A3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011110488-A1 | A NOVEL PET IMAGING AGENT OF AMYLOID PLAQUES AND ITS PRECURSOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110511-A1 | SPECT IMAGING AGENTS OF AMYLOID PLAQUES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| EP-0610140-B1 | 2-[4-(4-Azolylbutyl)-1-piperazinyl]-5-hydroxypyrimidin derivatives, their preparation and their use as medicines | ESTEVE LABOR DR (ES) | 2000-01-12 | — | — | EP | disclosed |
| US-5444059-A | Anxiolytic agents | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 1995-08-22 | — | — | US | disclosed |
| EP-0610140-A1 | 2- 4-(4-Azolylbutyl)-1-piperazinyl -5-hydroxypyrimidin derivatives, their preparation and their use als medicines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1994-08-10 | — | — | EP | disclosed |
| EP-0200968-B1 | SUCCINIMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4423049-A | TRANQUILIZERS | MEAD JOHNSON & COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | TAAR1 263/4885SLC6A2 492/4885SLC6A3 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.